|
1
|
Chang JS, Chen LT, Shan YS, Lin SF, Hsiao
SY, Tsai CR, Yu SJ and Tsai HJ: Comprehensive analysis of the
incidence and survival patterns of lung cancer by histologies,
including rare subtypes, in the era of molecular medicine and
targeted therapy: A nation-wide cancer registry-based study from
Taiwan. Medicine (Baltimore). 94:e9692015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cho JH: Immunotherapy for non-small-cell
lung cancer: Current status and future obstacles. Immune Netw.
17:378–391. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kiura K, Ueoka H, Segawa Y, Tabata M,
Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi K, et
al: Phase I/II study of docetaxel and cisplatin with concurrent
thoracic radiation therapy for locally advanced non-small-cell lung
cancer. Br J Cancer. 89:795–802. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS,
Teng D and Lee KD: Overall survival benefits of first-line EGFR
tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung
cancers: A systematic review and meta-analysis. Br J Cancer.
113:1519–1528. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stinchcombe TE: Targeted therapies for
lung cancer. Cancer Treat Res. 170:165–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thatcher N, Chang A, Parikh P, Rodrigues
Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V and Carroll K: Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell Lung Cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tiseo M, Rossi G, Capelletti M, Sartori G,
Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C,
Campanini N, et al: Predictors of gefitinib outcomes in advanced
non-small lung cancer (NSCLC): Study of a comprehensive panel of
molecular markers. Lung Canser. 67:355–360. 2010. View Article : Google Scholar
|
|
11
|
Rusch VW, Rice TW, Crowley J, Blackstone
EH, Rami-Porta R and Goldstraw P: The seventh edition of the
american joint committee on cancer/international union against
cancer staging manuals: The new era of data-driven revisions. J
Thorac Cardiovasc Surg. 139:819–821. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumors:
Recist guideline (version 1.1). Eur J Cancer. 47:228–247. 2009.
View Article : Google Scholar
|
|
14
|
Lakshman A, Modi M, Prakash G, Malhotra P,
Khadwal A, Jain S, Kumari S, Varma N and Varma S: Evaluation of
bortezomib-induced neuropathy using total neuropathy score (Reduced
and Clinical Versions) and NCI CTCAE v4.0 in newly diagnosed
patients with multiple myeloma receiving bortezomib-based
induction. Clin Lymphoma Myeloma Leuk. 17:513–519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inoue A, Kobayashi K, Maemondo M, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Updated overall survival
results from a randomized phase III trial comparing gefitinib with
carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer
with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 24:54–59.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen G, Feng J, Zhou C, Wu YL, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Quality of life
(QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised,
open-label study of first-line erlotinib versus chemotherapy in
patients with advanced EGFR mutation-positive non-small-cell lung
cancer (NSCLC). Ann Oncol. 24:1615–1622. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish lung cancer group in
collaboration with groupe français de pneumo-cancérologie and
associazione italiana oncologia toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Saijo N, et al: Biomarker analyses and final overall survival
results from a phase III, randomized, open-label, first-line study
of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han JY, Park K, Kim SW, Lee DH, Kim HY,
Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL:
First-line single-agent iressa versus gemcitabine and cisplatin
trial in never-smokers with adenocarcinoma of the lung. J Clin
Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Banno E, Togashi Y, Kobayashi Y, Hayashi
H, Mitsudomi T and Nishio K: Afatinib is especially effective
against non-small cell lung cancer carrying an EGFR exon 19
deletion. Anticancer Res. 35:2005–2008. 2015.PubMed/NCBI
|
|
24
|
Fukuhara T, Maemondo M, Inoue A, Kobayashi
K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H,
et al: Factors associated with a poor response to gefitinib in the
NEJ002 study: Smoking and the L858R mutation. Lung Cancer.
88:181–186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Sheng J, Kang S, Fang W, Yan Y,
Hu Z, Hong S, Wu X, Qin T, Liang W and Zhang L: Patients with exon
19 deletion were associated with longer progression-free survival
compared to those with L858R mutation after first-line EGFR-TKIs
for advanced non-small cell lung cancer: A meta-analysis. PLoS One.
9:e1071612014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Igawa S, Kasajima M, Ishihara M, Kimura M,
Hiyoshi Y, Asakuma M, Otani S, Katono K, Sasaki J and Masuda N:
Comparison of the efficacy of gefitinib in patients with non-small
cell lung cancer according to the type ofepidermal growth factor
receptor mutation. Oncology. 87:215–223. 2014. View Article : Google Scholar : PubMed/NCBI
|
